...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Free
Due Dilligence

ASN Kidney Week BETonMACE CKD Oral Presentation 10/24/2020

Posted by: BearDownAZ on Oct 25, 2020 06:21PM
URL: https://www.resverlogix.com/upload/media...8d8/kalantar_apabetalone_asn2020_v05.pdf

GCFF Virtual Conference 9/10/2020 - Investing in Innovation

Posted by: BearDownAZ on Sep 12, 2020 02:43PM
URL: https://www.resverlogix.com/upload/media...500-virtual-innovation-sept.-10-ench.pdf

Epigenetic Therapeutic Targets Virtual Summit Presentation July 28, 2020

Posted by: BearDownAZ on Jul 28, 2020 10:31PM
URL: https://www.resverlogix.com/upload/media...pigenetic-therapeutic-targets---wong.pdf
Resverlogix Corp. Links

Apabetalone and hospitalization for heart failure in patients following an acute coronary syndrome: a prespecified analysis of the BETonMACE study

Posted by: BearDownAZ on Jan 12, 2021 08:05AM
URL: https://cardiab.biomedcentral.com/articles/10.1186/s12933-020-01199-x

AGM 12/22/2020 transcript c/o imtesty

Posted by: BearDownAZ on Jan 06, 2021 10:54AM
URL: https://agoracom.com/ir/Resverlogix/foru...ough-transcript/messages/2295324#message

AHA 2020: Reduction in the Risk of Major Adverse Cardiovascular Events with Apabetalone, a BET Protein Inhibitor, in Patients withRecent Acute Coronary Syndrome and Type 2 Diabetes According to Insulin Treatment: Analysis of the BETonMACE Trial

Posted by: BearDownAZ on Nov 16, 2020 10:23AM
URL: https://www.resverlogix.com/upload/media...lin-aha-2020_05-nov-2020---read-only.pdf

AHA 2020: BET Protein Inhibitor Apabetalone Suppresses Inflammatory Hyperactivation of Monocytes from Patients with Cardiovascular Disease and Type 2 Diabetes

Posted by: BearDownAZ on Nov 14, 2020 05:28PM
URL: https://www.resverlogix.com/upload/media...ee0/2020-10-05-mela-aha-presentation.pdf

AHA 2020: Apabetalone (RVX-208) Reduces ACE2 Expression in Human Cell Culture Systems, Which Could Attenuate SARS-CoV-2 Viral Entry

Posted by: BearDownAZ on Nov 14, 2020 05:27PM
URL: https://www.resverlogix.com/upload/media...ha-2020-covid-19_eposter.final.dg.lf.pdf

Cardiovascular Therapeutics article: Epigenetic Modulation by Apabetalone Counters Cytokine-Driven Acute Phase Response In Vitro, in Mice and in Patients with Cardiovascular Disease

Posted by: BearDownAZ on Nov 14, 2020 05:25PM
URL: https://www.hindawi.com/journals/cdtp/2020/9397109/

Medicinal Research Reviews article: Inhibitors of bromodomain and extra-terminal proteins for treating multiple human diseases

Posted by: BearDownAZ on Nov 14, 2020 05:24PM
URL: https://onlinelibrary.wiley.com/doi/epdf/10.1002/med.21730

Clinical Epigenetics Publication: BET protein inhibitor apabetalone (RVX-208) suppresses pro-inflammatory hyper-activation of monocytes from patients with cardiovascular disease and type 2 diabetes

Posted by: BearDownAZ on Nov 14, 2020 05:22PM
URL: https://clinicalepigeneticsjournal.biome....com/articles/10.1186/s13148-020-00943-0

CTAD 2020 Poster: The Epigenetic BET Protein Inhibitor Apabetalone Counters Brain Endothelial Activation and Monocyte Adhesion

Posted by: BearDownAZ on Nov 05, 2020 10:11PM
URL: https://www.resverlogix.com/upload/media...05-ctad-2020-neuroinflammation-final.pdf

ASN Kidney Week 2020 Poster: Apabetalone, an Inhibitor of BET Proteins, Downregulates Alkaline Phosphatase and Improves Cardiovascular Risk

Posted by: BearDownAZ on Oct 25, 2020 09:06PM
URL: https://www.resverlogix.com/upload/media...alp-phase-2-in-vitro-poster-final.dg.pdf